Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ASN008
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASN008, a Phase 2-ready topical sodium channel blocker in development for atopic dermatitis. ASN008 has shown promising efficacy data in pruritus (itch) associated with atopic dermatitis.
Brand Name : ASN008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2023
Lead Product(s) : ASN008
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : resTORbio
Deal Size : Undisclosed
Deal Type : Collaboration
Details : TrialSpark's integrated tech platform and trial model will enable resTORbio to accelerate their clinical trials of RTB-101 for COVID-19 in community/outpatient settings.
Brand Name : RTB-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : Dactolisib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : resTORbio
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?